Investigative Ophthalmology & Visual Science, Vol 36, 1215-1230, Copyright © 1995 by Association for Research in Vision and Ophthalmology

ARTICLES AND REPORTS

Supplemental oxygen therapy. Basis for noninvasive treatment of retinopathy of prematurity

CL Tailoi, B Gock and J Stone
Department of Anatomy and Histology, University of Sydney, Australia.

PURPOSE. To determine the effectiveness of supplemental oxygen therapy (SOT) in ameliorating the proliferative vasculopathy characteristic of the feline model of retinopathy of prematurity (ROP). METHODS. Kittens were exposed to high (70% to 80%) oxygen for the first 4 days of life to induce obliteration of the retinal circulation. The level of inspired oxygen at successive stages after hyperoxia were varied systematically, and the retinas were examined for the extent of revascularization, astrocyte survival, intactness of the blood-retinal barrier, and extent of preretinal vessels. RESULTS. The level of inspired oxygen required to protect the retina from hypoxic damage and yet provide a stimulus for growth of the vasculature varied during a 6- week period. The rate of revascularization of the retina increased as the oxygen content of the inspired gas mixture decreased, with a consequential increase in the pathology observed. However, a regimen that produced a quicker rate of revascularization with a slightly higher level of pathology actually offered the retina greater protection in the long term. The formation of preretinal vessels was effectively prevented by SOT. Supplemental oxygen therapy could be terminated once a significant portion of the retina was revascularized. CONCLUSIONS. The proliferative vasculopathy of a kitten model of ROP can be significantly reduced by a regimen of SOT, which attempts to mimic physiological levels of hypoxia in the retina during its revascularization. Optimal revascularization requires a balance between the rate and quality of vessel growth. With further refinement of the protocol, SOT could provide noninvasive treatment of ROP in neonates.

This article has been cited by other articles:

				Y. Saito, A. Uppal, G. Byfield, S. Budd, and M. E. Hartnett Activated NAD(P)H Oxidase from Supplemental Oxygen Induces Neovascularization Independent of VEGF in Retinopathy of Prematurity Model Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1591 - 1598. [Abstract] [Full Text] [PDF]

				S. Hughes, T. Gardiner, L. Baxter, and T. Chan-Ling Changes in Pericytes and Smooth Muscle Cells in the Kitten Model of Retinopathy of Prematurity: Implications for Plus Disease Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 1368 - 1379. [Abstract] [Full Text] [PDF]

				T. Chan-Ling, M. P. Page, T. Gardiner, L. Baxter, E. Rosinova, and S. Hughes Desmin Ensheathment Ratio as an Indicator of Vessel Stability: Evidence in Normal Development and in Retinopathy of Prematurity Am. J. Pathol., October 1, 2004; 165(4): 1301 - 1313. [Abstract] [Full Text] [PDF]

				N. Simakajornboon, R. C. Beckerman, C. Mack, D. Sharon, and D. Gozal Effect of Supplemental Oxygen on Sleep Architecture and Cardiorespiratory Events in Preterm Infants Pediatrics, November 1, 2002; 110(5): 884 - 888. [Abstract] [Full Text] [PDF]

				X. Gu, S. Samuel, M. El-shabrawey, R. B. Caldwell, M. Bartoli, D. M. Marcus, and S. E. Brooks Effects of Sustained Hyperoxia on Revascularization in Experimental Retinopathy of Prematurity Invest. Ophthalmol. Vis. Sci., February 1, 2002; 43(2): 496 - 502. [Abstract] [Full Text] [PDF]

				B. A. Berkowitz and W. Zhang Significant Reduction of the Panretinal Oxygenation Response after 28% Supplemental Oxygen Recovery in Experimental ROP Invest. Ophthalmol. Vis. Sci., June 1, 2000; 41(7): 1925 - 1931. [Abstract] [Full Text]

				S. Hughes, H. Yang, and T. Chan-Ling Vascularization of the Human Fetal Retina: Roles of Vasculogenesis and Angiogenesis Invest. Ophthalmol. Vis. Sci., April 1, 2000; 41(5): 1217 - 1228. [Abstract] [Full Text]

				The STOP-ROP Multicenter Study Group Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), A Randomized, Controlled Trial. I: Primary Outcomes Pediatrics, February 1, 2000; 105(2): 295 - 310. [Abstract] [Full Text]